AlphaCore Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AlphaCore Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$835K	Sell	5,296 -728	-12%	-$115K	0.01%	578
2026 Q2	$953K	Sell	6,024 -1,298	-18%	-$175K	0.02%	480
2026 Q1	$935K	Sell	7,322 -328	-4%	-$40.9K	0.02%	403
2025 Q4	$933K	Buy	7,650 +7,210	+1,639%	+$827K	0.02%	436
2025 Q3	$44.1K	Sell	440 -100	-19%	-$9.01K	﹤0.01%	883
2025 Q2	$44.8K	Buy	540 +532	+6,650%	+$42.4K	﹤0.01%	825
2025 Q1	$675	Buy	+8	New	+$715	﹤0.01%	764
2024 Q1	–	Sell	-1,429	Closed	-$128K	–	392
2023 Q4	$128K	Buy	+1,429	New	+$106K	0.02%	240
2023 Q3	–	Sell	-100	Closed	-$8.32K	–	383
2023 Q2	$8.32K	Hold	100	–	–	﹤0.01%	305
2023 Q1	$7.62K	Buy	+100	New	+$8.3K	﹤0.01%	205
2021 Q4	–	Sell	-200	Closed	-$25K	–	135
2021 Q3	$25K	Buy	+200	New	+$25.8K	0.01%	93

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

AlphaCore Capital's XBI Position: Q3 2026 in Review

AlphaCore Capital reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 12% in Q3 2026, selling an estimated $115K and leaving 5,296 shares worth $835K. The position accounts for 0.01% of the portfolio, ranked #578.

AlphaCore Capital first reported a position in XBI in Q3 2021 and has held it in 11 quarters since. The position peaked at $953K in Q2 2026. 521 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

AlphaCore Capital held 5,296 shares of State Street SPDR S&P Biotech ETF worth $835K as of Q3 2026.
AlphaCore Capital sold 728 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $115K.
State Street SPDR S&P Biotech ETF made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #578 holding.
AlphaCore Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 11 quarters since.
AlphaCore Capital's State Street SPDR S&P Biotech ETF position peaked at $953K in Q2 2026.
521 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.